Nam Kyungpil Appointed Chairman of Biotech Firm GemVax: "We Will Commercialize Our Research Achievements"

Inauguration Ceremony Held in Yeouido, Seoul on June 17
Chairman Nam, Former Governor of Gyeonggi Province
Highlights 'Commercialization' in His Inaugural Address

"I will pave a solid path to ensure that ZEMVEX's outstanding research achievements can be successfully established in the market and, ultimately, reach patients."

Nam Kyungpil, the newly appointed chairman of ZEMVEX and Kael, made this statement at his inauguration ceremony held at the Korea Exchange in Yeongdeungpo-gu, Seoul, on the morning of the 17th. Chairman Nam presented a management vision focused on respecting expertise and strengthening collaboration, emphasizing, "My core responsibility is to align everyone's strongest capabilities in a single direction." He expressed his ambition to maximize synergy within the organization and elevate the company's value to the next level. ZEMVEX is a biotech company developing new drugs for central nervous system (CNS) diseases, including Alzheimer's disease and progressive supranuclear palsy (PSP). Through its core pipeline, GV1001, the company is advancing clinical trials to take the lead in the rare degenerative brain disease market—such as progressive supranuclear palsy, which currently lacks any approved treatments.

Nam Kyungpil, the newly appointed chairman of ZEMVEX and Kael, is speaking at the inauguration ceremony held at the Korea Exchange in Yeongdeungpo-gu, Seoul, on the morning of the 17th. Photo by Jeong Donghoon

Chairman Nam further stressed the importance of communication in connecting ZEMVEX's outstanding research achievements with patients and the market. He stated, "Despite producing excellent research results, we have not always succeeded in properly communicating them to the world," adding, "Our ultimate goal is for our research not to end as research, but to reach patients not only in Korea, but around the world." This demonstrates his intention to firmly establish ZEMVEX not just as a research-driven company, but as a global biotech enterprise that produces tangible commercial results.

In-depth academic presentations by experts followed, explaining the clinical results and mechanism of action of ZEMVEX's new drug pipeline, GV1001—the key driver of this vision. Lee Seokjun, CEO of ZEMVEX, said, "GV1001 is a multi-target drug that simultaneously blocks protein aggregation, mitochondrial dysfunction, and neuroinflammation, which are common causes of neurodegenerative diseases. In the global PSP market, where there are currently no approved treatments, we have laid the foundation for market exclusivity by obtaining Fast Track designation from the U.S. Food and Drug Administration (FDA) and rare disease status in Korea, the U.S., and Europe, based on significant results from our domestic Phase 2 trial."

Medical opinions on the potential of GV1001 were also presented. Lee Jaehong, professor of neurology at Asan Medical Center in Seoul, explained, "PSP is a disease in which toxic tau proteins accumulate in the brain, causing chronic inflammation and killing nerve cells. All previous single-target drugs have failed in clinical trials. GV1001, with its multi-target mechanism, not only suppresses severe brain inflammation and prevents oxidative brain damage, but also normalizes the mitochondrial energy system to protect nerve cells, making it highly likely to show positive effects in future clinical studies."

In fact, results from the domestic Phase 2a exploratory clinical trial showed that the GV1001 treatment group experienced approximately 50% slower disease progression compared to the placebo group, demonstrating a statistically significant inhibitory effect on disease advancement. Particularly in the low-dose treatment group, improvements were observed not only in preventing deterioration of motor functions, but also in cognitive function indicators. The 72-week extension study also confirmed excellent long-term tolerability and efficacy, providing a solid basis for advancing into global pivotal clinical trials.

A representative from ZEMVEX stated, "With new leadership, we will re-examine our current business direction and create a turning point to grow beyond an R&D-focused company into a global enterprise. Please look forward to ZEMVEX's progress as we continue to advance, grounded in scientific evidence."

This content was produced with the assistance of AI translation services.